Skip to main content

Lung Cancer

Lung Cancer, Oncology
A Look at PD-1 and PD-L1 Inhibitors
Edward Garon, MD
Play Video
Lung Cancer, Oncology
Adjuvant Osimertinib a Practice-­Changing Treatment in Early-Stage NSCLC with EGFR Mutation
Wayne Kuznar
Wayne Kuznar
Play Video
Lung Cancer, Oncology
Afatinib Boosts PFS in EGFR Mutation–Positive Lung Cancer
Wayne Kuznar
Play Video
Lung Cancer, Oncology
Afatinib Doubles Progression-Free Survival Compared with Chemotherapy in Patients with Lung Cancer
Wayne Kuznar
Play Video
Lung Cancer, Oncology
Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Phoebe Starr
Play Video
Lung Cancer, Oncology
Alectinib Potential First-Line Treatment for NSCLC Associated with ALK Mutation
Wayne Kuznar
Play Video
Lung Cancer, Oncology
ALK Gene Rearrangement and PD-L1 Expression
Edward Garon, MD
Play Video
Lung Cancer, Payers' Guide, FDA Approvals, Oncology
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh
Play Video
Conference Highlights ASCO, Lung Cancer, Oncology
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
Phoebe Starr
Phoebe Starr
Play Video
Lung Cancer, Oncology
BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion
Wayne Kuznar
Wayne Kuznar
Play Video
Page 1 of 5
Results 1 - 10 of 44